Castle Biosciences Webinar

Cutaneous melanoma (CM) is one of the fastest growing malignancies in the U.S., with more than 90,000 cases diagnosed and nearly 10,000 deaths each year. CM management guidelines indicate that management decisions should ultimately be tailored to an individual’s probability of recurrence or sentinel lymph node (SLN) positivity. Join us in this webinar for an understanding risk of metastatic disease is essential in the management of CM patients as it provides information for treatment decisions, such as performance of SLNB or intensity of follow up and surveillance imaging that can improve patient care.